Key result
In patients with ischemic heart disease undergoing noncardiac surgery, β-blocker therapy was associated with lower 30-day MACE only in those with heart failure (HR 0.75; 95% CI 0.70-0.87) or recent MI.
Why the study?
Does β-blocker therapy reduce 30-day MACE and all-cause mortality in patients with ischemic heart disease undergoing noncardiac surgery?
Cohort (n=28,263)
Yes
Does β-blocker therapy reduce 30-day MACE and all-cause mortality in patients with ischemic heart disease undergoing noncardiac surgery?
Hazard Ratio: 0.9 (95% CI 0.79–1.02)
Perioperative β-blocker therapy in patients with ischemic heart disease undergoing noncardiac surgery is associated with reduced 30-day cardiovascular events only in those with concurrent heart failure or a recent myocardial infarction.
No takes yet. Share an insight, caveat, or question.
May support β-blocker use in ischemic heart disease with heart failure; leaves open benefit without heart failure or recent MI.
Andersson et al. (2013) conducted a cohort in Ischemic heart disease undergoing noncardiac surgery (n=28,263). β-blocker therapy vs. No β-blocker therapy was evaluated on 30-day risk of MACE (ischemic stroke, myocardial infarction, or cardiovascular death) (HR 0.90, 95% CI 0.79-1.02). In patients with ischemic heart disease undergoing noncardiac surgery, β-blocker therapy was associated with lower 30-day MACE only in those with heart failure (HR 0.75; 95% CI 0.70-0.87) or recent MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: